DealBook: Priceline.com to Buy Kayak for $1.8 Billion

Just months after going public, Kayak Software has been snapped up by a rival.

On Thursday, Priceline.com, a travel company from an earlier Internet age, agreed to buy Kayak, a younger competitor, for $1.8 billion in cash and stock.

The acquisition, the largest in Priceline’s history, could provide a new source of revenue for the company.

Priceline, once a highflying company that survived the dot-com bubble in the late 1990s, acts as an online travel agent. It collects fees and commissions on reservations. Kayak, which was started in 2004, allows users to search other sites to compare prices. It makes most of its money from referrals and advertising.

“I see Kayak serving as a global entree into the advertising market for Priceline,” said Daniel Kurnos, an analyst at the Benchmark Company. He said the deal could help Priceline “with their search rankings and give them some additional expertise in the technology department.”

The companies’ global ambitions are also symbiotic. Priceline, which also owns the Asian travel site Agoda.com, has been pushing into new markets overseas. International reservations accounted for 78 percent of its total last year.

In the third quarter, Kayak’s revenue from outside the United States amounted to $17.3 million, a 40 percent increase from the period a year earlier, the company said when it reported earnings on Thursday. Overall third-quarter revenue rose 29 percent, to $78.6 million.

“We believe we can be helpful with Kayak’s plans to build a global online travel brand,” Priceline’s chief executive, Jeffery H. Boyd, said in a statement.

The deal is yet another corporate evolution for Kayak. In a matter of months, the travel search site has gone from a privately held start-up to a publicly traded company to a unit operating under the umbrella of Priceline.

Following a long path to the public markets that started in 2010, Kayak got a relatively warm reception from investors in its July debut. Just months after the troubled offering of Facebook, shares of Kayak surged on their first day of trading, closing at roughly $33. Since then, the stock has fluctuated.

Priceline will pay roughly $40 a share for Kayak. At that level, the acquisition represents a 29 percent premium over Kayak’s closing price of $31.04 a share on Thursday. The transaction is expected to close in the first quarter of next year.

“We’re excited to join the world’s premier online travel company,” Steve Hafner, Kayak’s chief executive, said in a statement.

Read More..

Ask an Expert: Wondering About Alzheimer’s? Ask Here

This week’s Ask the Expert features Dr. P. Murali Doraiswamy, who will answer questions related to Alzheimer’s disease and memory loss. He is a professor of psychiatry at Duke University Medical Center and an author of “The Alzheimer’s Action Plan.” Dr. Doraiswamy has also served as an adviser to government agencies, advocacy groups and businesses.

About five million Americans today live with Alzheimer’s disease, and a new diagnosis is made about every 70 seconds. Cases are expected to triple over the coming decades as baby boomers age.

Misperceptions and misdiagnoses are common about Alzheimer’s, which ranks second to only cancer among diseases that adults fear the most. Many people do not understand that there are dozens of causes for memory loss besides Alzheimer’s, including many that can be fully reversed if caught early.

Among the questions Dr. Doraiswamy is prepared to answer:

What are the best tests to determine if it is or isn’t Alzheimer’s?

How do you determine your own risk?

What are the family-care options? Medications for memory? Medications for behavior problems? Preventive strategies?

What has been learned from the latest clinical trials?

How can you improve your memory?

Please leave your questions in the comments section. Answers will be posted on Wednesday.

You can follow Booming via RSS here or visit nytimes.com/booming.

Read More..

Ask an Expert: Wondering About Alzheimer’s? Ask Here

This week’s Ask the Expert features Dr. P. Murali Doraiswamy, who will answer questions related to Alzheimer’s disease and memory loss. He is a professor of psychiatry at Duke University Medical Center and an author of “The Alzheimer’s Action Plan.” Dr. Doraiswamy has also served as an adviser to government agencies, advocacy groups and businesses.

About five million Americans today live with Alzheimer’s disease, and a new diagnosis is made about every 70 seconds. Cases are expected to triple over the coming decades as baby boomers age.

Misperceptions and misdiagnoses are common about Alzheimer’s, which ranks second to only cancer among diseases that adults fear the most. Many people do not understand that there are dozens of causes for memory loss besides Alzheimer’s, including many that can be fully reversed if caught early.

Among the questions Dr. Doraiswamy is prepared to answer:

What are the best tests to determine if it is or isn’t Alzheimer’s?

How do you determine your own risk?

What are the family-care options? Medications for memory? Medications for behavior problems? Preventive strategies?

What has been learned from the latest clinical trials?

How can you improve your memory?

Please leave your questions in the comments section. Answers will be posted on Wednesday.

You can follow Booming via RSS here or visit nytimes.com/booming.

Read More..

Popular Wrench Fights a Chinese Rival

John Gress for The New York Times

Dan Brown, inventor of the Bionic Wrench, is defending his patent rights against the Max Axess, made in China.

Last Christmas, Sears had a brisk seller in the Bionic Wrench, an award-winning, patented tool with spiffy lime green accents. This holiday season, though, Sears has a special display for its own wrench, in the red and black colors of its house brand, Craftsman.

William P. O'Donnell/The New Yortk Times

The Bionic Wrench is made in America by Penn United Technologies. Sears sells the Max Axess, sourced from China.

One customer who recently spotted the new Craftsman tool, called the Max Axess wrench, thought it was an obvious knockoff, right down to the try-me packaging. “I saw it and I said, ‘This is a Bionic Wrench,’ ” recalled Dana Craig, a retiree and tool enthusiast in Massachusetts who alerted the maker of the Bionic Wrench. “It’s a very distinctive tool,” he added.

The tools have one significant difference, Mr. Craig noted. The Bionic Wrench is made in the United States. The Max Axess wrench is made in China.

The shift at Sears from a tool invented and manufactured in the United States to a very similar one made offshore has already led to a loss of American jobs and a brewing patent battle.

The story of the Bionic Wrench versus Craftsman, which bills itself as “America’s most trusted tool brand,” also raises questions about how much entrepreneurs and innovators, who rely on the country’s intellectual property laws, can protect themselves. For the little guy, court battles are inevitably time-consuming and costly, no matter the outcome.

Still, the inventor of the Bionic Wrench is determined to fight. He is Dan Brown, an industrial designer in Chicago who came up with the wrench after watching his son try to work on a lawn mower. Mr. Brown says he believes that the Max Axess wrench copies his own and he is planning to file suit against Sears, which declined to answer any questions about the wrenches for this article.

The Bionic Wrench is distinguished by its gripping mechanism, a circle of metal prongs that, inspired by the shutter in a single-lens reflex camera, descend evenly to lock onto almost any nut or bolt.

Since Sears has halted new orders, the Pennsylvania company that makes the Bionic Wrench has had to lay off 31 workers, said Keith Hammer, the project manager at the company, Penn United Technologies. “And that’s not to mention our suppliers,” he added.

Mr. Brown sees a broader issue than just the fate of his wrench. “Our situation is an example of why we’re not getting jobs out of innovation,” he said. “When people get the innovation, they go right offshore. What happened to me is what happened to so many people so many times, and we just don’t talk about it.”

Inventors typically spend $10,000 to $50,000 to obtain the type of patent Mr. Brown has on the wrench, said John S. Pratt, a patent expert at Kilpatrick Townsend & Stockton in Atlanta. Though he said he could not comment on the merits of Mr. Brown’s potential suit, patent infringement cases can be especially difficult in the tool field, where many improvements are incremental, Mr. Pratt explained.

A defendant in such a case would most likely argue that either the tool did not warrant a patent in the first place, or that its own product did not violate the patent.

The fact that Sears made some changes to the wrench’s design, like making the grooves that allow the metal prongs to slide back and forth visible instead of hidden, will make the case more challenging, he said. “It’s hard for me to imagine that Sears isn’t particularly careful about breach of patent, so there’s probably another side to the story,” he said.

After patenting the wrench in 2005, Mr. Brown formed a company, LoggerHead Tools, to bring it to market, making a point of having it made in the United States.

The Bionic Wrench was greeted with enthusiasm at trade shows and in industrial design competitions, and the company survived the downturn in 2008. Mr. Brown resisted overtures from large chain stores that wanted to sell the tool under their proprietary brand, he said, and rejected the lure of cheaper manufacturing in China. “I was raised a different way,” he said.

The tool sold fairly well on its own — LoggerHead has shipped 1.75 million of them — but Mr. Brown, 56, who teaches industrial design at Northwestern University, says LoggerHead operated on a shoestring and he plowed much of the profit back into the company. “You cannot have big offices and fancy cars and everybody with an administrative assistant, because we are competing with China,” he said.

Read More..

China Prepares for Party Congress and Leadership Transition

Diego Azubel/European Pressphoto Agency

Soldiers marched past the Great Hall of the People in Beijing on Wednesday, on the eve of the 18th Communist Party Congress.

BEIJING — With a robust defense of one-party rule and a vow to learn from a string of political scandals this year, a senior official on Wednesday laid out the agenda for China’s much-anticipated Communist Party Congress, which gets under way on Thursday.

The weeklong congress is expected to cap a long and at times fractious transition from the current leadership of Hu Jintao to his presumed successor, Xi Jinping. If all goes according to plan, Mr. Xi and half a dozen other top leaders will be presented to the public next Thursday.

Officially, the new team is to be selected in the coming week by the 2,280 delegates participating in this congress, the 18th in the party’s 91-year history. Delegates are also scheduled to discuss a work report that is to lay out in broad strokes the country’s future course over the next five years, and approve it along with a report on anticorruption measures.

In fact, much of what will go on during the congress has already been decided. The delegates are voted on by lower-ranking members but based on guidance provided by higher-ups, a process known as “democratic centralism.” So, too, the work and corruption reports, which will be discussed by the delegates but are not expected to be substantially altered before being approved.

At a news conference on Wednesday, the congress’s spokesman and deputy head of Communist Party propaganda, Cai Mingzhao, defended this system as one that allows members to express their views in a controlled setting.

“We must combine centralism on the basis of democracy, with democracy under centralized guidance so that we will create a political situation in the party in which we have both centralism and democracy, both discipline and freedom, both unity of will and personal ease of mind,” Mr. Cai said.

He also said the Communist Party had earned the right to rule China.

“The leading position of the Communist Party in China is a decision made by history and by the people,” Mr. Cai said. “Political system reform must suit China’s national reality.”

Mr. Cai seemed to pour cold water on widespread reports that the party was planning to reform its internal elections, for example by having more candidates than slots for top bodies. That would allow delegates to vote out unpopular leaders. He said votes would be secret and some multicandidate elections would take place, but all would be “in accordance with the electoral method adopted by the congress.”

That is not to say that the congress’s decisions are already widely known.

Still uncertain is who will be next to Mr. Xi when the top leadership is presented in a week. This group, known as the Politburo Standing Committee, essentially runs China.

According to plan, it will include Mr. Xi and Li Keqiang, who is expected to take over as head of the government bureaucracy next year. Both men are current members of the Standing Committee.

It is also unclear how many members the committee will have. It currently has nine posts, and is expected to be reduced to seven.

Pundits have been speculating on who the other members will be and what various appointments might mean for China’s direction. But even last week, new names and combinations were making the rounds in Beijing, indicating that party leaders and their various factions were still vying to put forward their candidates.

Mr. Cai also said the party had learned from the scandals surrounding two high-ranking officials: the former Politburo member Bo Xilai and the former railway minister Liu Zhijun. Both have been accused of corruption, although Mr. Bo is also accused of covering up the murder of a British businessman. “The lessons are profound,” said Mr. Cai, who added that the party would pursue strong anticorruption measures.

Mr. Cai also said the congress would pursue reforms and work on a “master reform plan on income distribution” to more equitably divide China’s growing economy. The country has one of the biggest gaps between rich and poor in the world, leading to frequent bouts of unrest and violence.

“In this way, we will make the fruits of reform and opening up benefit our people more and in a more equitable fashion,” Mr. Cai said.

Read More..

Apples Stock Sinks as Profits and Products Are Questioned

Autumn is traditionally the time of year when people start snapping up Apple products. It’s also when investors, in anticipation of another blockbuster holiday season from the company, do the same with Apple shares.

But this year, even though Apple’s iPhones and iPads don’t seem to have lost any of their allure for holiday shoppers, its stock seems headed straight for the discount rack.

On Wednesday, Apple’s shares slid 3.8 percent. They outpaced a broader decline in the stock market set off by investors’ uncertainty about how the outcome of the presidential election will affect taxes and consumer demand for the types of products Apple sells.

During the campaign, President Obama proposed increasing capital gains tax rates for people earning over $250,000 to 20 percent from the existing rate of 15 percent, and his re-election Tuesday night may have prompted some investors to unload shares in anticipation of a broader sell-off in stocks ahead of a tax increase, analysts said.

Owners of Apple shares would have good reason to fear higher taxes on capital gains. Apple shares have appreciated mightily since 2005 when they were about $35 apiece; they began this year at $411 and peaked at more than $700 in late September. The drop on Wednesday only added to what has been a grim few weeks for Apple shares, which have fallen over 20 percent from that peak, to $558 on Wednesday.

The decline has followed a sequence of seemingly unrelated events, including a broader-than-normal overhaul of its product line that is expected to hurt profit margins in the near term and a rare shake-up in Apple’s senior ranks.

“It has just been wave after wave of bad news,” said Gene Munster, an analyst at Piper Jaffray.

The events also do little to diminish the questions reflecting longer-term concerns with which investors pepper analysts like Mr. Munster. How much bigger can Apple — with a $525 billion market value, the biggest of any corporation — get? Won’t Apple soon run out of people to sell iPhones, iPads and Macs to?

Those concerns have been one of the biggest reasons Apple’s stock has long traded at a discount, strange as that may sound, to its peers in the tech business. Apple’s forward price-to-earnings ratio — the value of the company’s stock divided by its expected earnings per share for the coming year — is just under 10.

That figure is 14 for Google, 32 for Facebook and 131 for Amazon. Steve Dowling, a spokesman for Apple, said the company generally did not comment on its share price.

Apple executives have said they still see huge opportunities for the company and it is still growing at a remarkable clip for a company its size. During its last fiscal year, which ended Sept. 29, Apple’s revenue jumped 45 percent to $156.51 billion and its profits rose 61 percent to $41.73 billion.

While Apple’s most recent financial report was mostly in line with Wall Street forecasts, the company warned that its profit margin would most likely decline in the holiday quarter because of a sweeping refresh of the company’s iPad, iMac and MacBook laptop lines.

Apple products often cost more to make during their first months on the market, but those costs come down as the process becomes more efficient and volumes increase. The company said its new iPad Mini would be among those products with low profit margins, raising concerns that Apple will make less money as it competes in lower-priced segments of the mobile market.

Apple’s worrisome financial report came just days before Apple announced the departure of Scott Forstall, the head of its mobile software development, in a move that it said was aimed at increasing collaboration between departments at the company. Apple split the responsibilities of Mr. Forstall, who was a divisive figure at the company, among an array of other Apple executives.

The surprise firing of Mr. Forstall was unusual for Apple, where turnover in its senior ranks is rare compared to other big technology companies.

Then late last week, the research firm IDC reported that 75 percent of smartphones shipped in the third quarter were Android phones, the main rival to Apple in mobile software. A year earlier, Google, the maker of Android software, had market share of 57.5 percent. The iPhone’s share rose at a much slower pace, jumping to 14.9 percent of shipments from 13.8 percent, IDC estimated.

But Apple is still making huge profits from the mobile market, far more than Google is. Even with the recent decline in its shares, Apple’s stock is still up 38 percent for the year.

David Rolfe, chief investment officer at Wedgewood Partners, which counts Apple as its biggest stock holding, said he remained confident that Apple was one of the best investments around.

“The bears think Apple is in the eighth inning,” Mr. Rolfe said. “We think they’re still in the fourth or fifth inning.”

Read More..

Ask an Expert: Wondering About Alzheimer’s? Ask Here

This week’s Ask the Expert features Dr. P. Murali Doraiswamy, who will answer questions related to Alzheimer’s disease and memory loss. He is a professor of psychiatry at Duke University Medical Center and an author of “The Alzheimer’s Action Plan.” Dr. Doraiswamy has also served as an adviser to government agencies, advocacy groups and businesses.

About five million Americans today live with Alzheimer’s disease, and a new diagnosis is made about every 70 seconds. Cases are expected to triple over the coming decades as baby boomers age.

Misperceptions and misdiagnoses are common about Alzheimer’s, which ranks second to only cancer among diseases that adults fear the most. Many people do not understand that there are dozens of causes for memory loss besides Alzheimer’s, including many that can be fully reversed if caught early.

Among the questions Dr. Doraiswamy is prepared to answer:

What are the best tests to determine if it is or isn’t Alzheimer’s?

How do you determine your own risk?

What are the family-care options? Medications for memory? Medications for behavior problems? Preventive strategies?

What has been learned from the latest clinical trials?

How can you improve your memory?

Please leave your questions in the comments section.

You can follow Booming via RSS here or visit nytimes.com/booming.

Read More..

Ask an Expert: Wondering About Alzheimer’s? Ask Here

This week’s Ask the Expert features Dr. P. Murali Doraiswamy, who will answer questions related to Alzheimer’s disease and memory loss. He is a professor of psychiatry at Duke University Medical Center and an author of “The Alzheimer’s Action Plan.” Dr. Doraiswamy has also served as an adviser to government agencies, advocacy groups and businesses.

About five million Americans today live with Alzheimer’s disease, and a new diagnosis is made about every 70 seconds. Cases are expected to triple over the coming decades as baby boomers age.

Misperceptions and misdiagnoses are common about Alzheimer’s, which ranks second to only cancer among diseases that adults fear the most. Many people do not understand that there are dozens of causes for memory loss besides Alzheimer’s, including many that can be fully reversed if caught early.

Among the questions Dr. Doraiswamy is prepared to answer:

What are the best tests to determine if it is or isn’t Alzheimer’s?

How do you determine your own risk?

What are the family-care options? Medications for memory? Medications for behavior problems? Preventive strategies?

What has been learned from the latest clinical trials?

How can you improve your memory?

Please leave your questions in the comments section.

You can follow Booming via RSS here or visit nytimes.com/booming.

Read More..

Apples Stock Sinks as Profits and Products Are Questioned

Autumn is traditionally the time of year when people start snapping up Apple products. It’s also when investors, in anticipation of another blockbuster holiday season from the company, do the same with Apple shares.

But this year, even though Apple’s iPhones and iPads don’t seem to have lost any of their allure for holiday shoppers, its stock seems headed straight for the discount rack.

On Wednesday, Apple’s shares slid 3.8 percent. They outpaced a broader decline in the stock market set off by investors’ uncertainty about how the outcome of the presidential election will affect taxes and consumer demand for the types of products Apple sells.

During the campaign, President Obama proposed increasing capital gains tax rates for people earning over $250,000 to 20 percent from the existing rate of 15 percent, and his re-election Tuesday night may have prompted some investors to unload shares in anticipation of a broader sell-off in stocks ahead of a tax increase, analysts said.

Owners of Apple shares would have good reason to fear higher taxes on capital gains. Apple shares have appreciated mightily since 2005 when they were about $35 apiece; they began this year at $411 and peaked at more than $700 in late September. The drop on Wednesday only added to what has been a grim few weeks for Apple shares, which have fallen over 20 percent from that peak, to $558 on Wednesday.

The decline has followed a sequence of seemingly unrelated events, including a broader-than-normal overhaul of its product line that is expected to hurt profit margins in the near term and a rare shake-up in Apple’s senior ranks.

“It has just been wave after wave of bad news,” said Gene Munster, an analyst at Piper Jaffray.

The events also do little to diminish the questions reflecting longer-term concerns with which investors pepper analysts like Mr. Munster. How much bigger can Apple — with a $525 billion market value, the biggest of any corporation — get? Won’t Apple soon run out of people to sell iPhones, iPads and Macs to?

Those concerns have been one of the biggest reasons Apple’s stock has long traded at a discount, strange as that may sound, to its peers in the tech business. Apple’s forward price-to-earnings ratio — the value of the company’s stock divided by its expected earnings per share for the coming year — is just under 10.

That figure is 14 for Google, 32 for Facebook and 131 for Amazon. Steve Dowling, a spokesman for Apple, said the company generally did not comment on its share price.

Apple executives have said they still see huge opportunities for the company and it is still growing at a remarkable clip for a company its size. During its last fiscal year, which ended Sept. 29, Apple’s revenue jumped 45 percent to $156.51 billion and its profits rose 61 percent to $41.73 billion.

While Apple’s most recent financial report was mostly in line with Wall Street forecasts, the company warned that its profit margin would most likely decline in the holiday quarter because of a sweeping refresh of the company’s iPad, iMac and MacBook laptop lines.

Apple products often cost more to make during their first months on the market, but those costs come down as the process becomes more efficient and volumes increase. The company said its new iPad Mini would be among those products with low profit margins, raising concerns that Apple will make less money as it competes in lower-priced segments of the mobile market.

Apple’s worrisome financial report came just days before Apple announced the departure of Scott Forstall, the head of its mobile software development, in a move that it said was aimed at increasing collaboration between departments at the company. Apple split the responsibilities of Mr. Forstall, who was a divisive figure at the company, among an array of other Apple executives.

The surprise firing of Mr. Forstall was unusual for Apple, where turnover in its senior ranks is rare compared to other big technology companies.

Then late last week, the research firm IDC reported that 75 percent of smartphones shipped in the third quarter were Android phones, the main rival to Apple in mobile software. A year earlier, Google, the maker of Android software, had market share of 57.5 percent. The iPhone’s share rose at a much slower pace, jumping to 14.9 percent of shipments from 13.8 percent, IDC estimated.

But Apple is still making huge profits from the mobile market, far more than Google is. Even with the recent decline in its shares, Apple’s stock is still up 38 percent for the year.

David Rolfe, chief investment officer at Wedgewood Partners, which counts Apple as its biggest stock holding, said he remained confident that Apple was one of the best investments around.

“The bears think Apple is in the eighth inning,” Mr. Rolfe said. “We think they’re still in the fourth or fifth inning.”

Read More..

Alarm Over India’s Dengue Fever Epidemic

Enrico Fabian for The New York Times

Filthy standing water abound in New Delhi has contributed to an epidemic of dengue fever in India. More Photos »

NEW DELHI — An epidemic of dengue fever in India is fostering a growing sense of alarm even as government officials here have publicly refused to acknowledge the scope of a problem that experts say is threatening hundreds of millions of people, not just in India but around the world.

India has become the focal point for a mosquito-borne plague that is sweeping the globe. Reported in just a handful of countries in the 1950s, dengue (pronounced DEN-gay) is now endemic in half the world’s nations.

“The global dengue problem is far worse than most people know, and it keeps getting worse,” said Dr. Raman Velayudhan, the World Health Organization’s lead dengue coordinator.

The tropical disease, though life-threatening for a tiny fraction of those infected, can be extremely painful. Growing numbers of Western tourists are returning from warm-weather vacations with the disease, which has reached the shores of the United States and Europe. Last month, health officials in Miami announced a case of locally acquired dengue infection.

Here in India’s capital, where areas of standing water contribute to the epidemic’s growth, hospitals are overrun and feverish patients are sharing beds and languishing in hallways. At Kalawati Saran Hospital, a pediatric facility, a large crowd of relatives lay on mats and blankets under the shade of a huge banyan tree outside the hospital entrance recently.

Among them was Neelam, who said her two grandchildren were deathly ill inside. Eight-year-old Sneha got the disease first, followed by Tanya, 7, she said. The girls’ parents treated them at home but then Sneha’s temperature rose to 104 degrees, a rash spread across her legs and shoulders, and her pain grew unbearable.

“Sneha has been given five liters of blood,” said Neelam, who has one name. “It is terrible.”

Officials say that 30,002 people in India had been sickened with dengue fever through October, a 59 percent jump from the 18,860 recorded for all of 2011. But the real number of Indians who get dengue fever annually is in the millions, several experts said.

“I’d conservatively estimate that there are 37 million dengue infections occurring every year in India, and maybe 227,500 hospitalizations,” said Dr. Scott Halstead, a tropical disease expert focused on dengue research.

A senior Indian government health official, who agreed to speak about the matter only on the condition of anonymity, acknowledged that official figures represent a mere sliver of dengue’s actual toll. The government only counts cases of dengue that come from public hospitals and that have been confirmed by laboratories, the official said. Such a census, “which was deliberated at the highest levels,” is a small subset that is nonetheless informative and comparable from one year to the next, he said.

“There is no denying that the actual number of cases would be much, much higher,” the official said. “Our interest has not been to arrive at an exact figure.”

The problem with that policy, said Dr. Manish Kakkar, a specialist at the Public Health Foundation of India, is that India’s “massive underreporting of cases” has contributed to the disease’s spread. Experts from around the world said that India’s failure to construct an adequate dengue surveillance system has impeded awareness of the illness’s vast reach, discouraged efforts to clean up the sources of the disease and slowed the search for a vaccine.

“When you look at the number of reported cases India has, it’s a joke,” said Dr. Harold S. Margolis, chief of the dengue branch at the Centers for Disease Control and Prevention in Atlanta.

Neighboring Sri Lanka, for instance, reported nearly three times as many dengue cases as India through August, according to the World Health Organization, even though India’s population is 60 times larger.

Hari Kumar contributed reporting.

Read More..